These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 28285023)

  • 41. A new rating scale for negative symptoms: the Motor-Affective-Social Scale.
    Trémeau F; Goggin M; Antonius D; Czobor P; Hill V; Citrome L
    Psychiatry Res; 2008 Sep; 160(3):346-55. PubMed ID: 18722021
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diagnostic validity of assessment scales for depression in patients with schizophrenia.
    Kim SW; Kim SJ; Yoon BH; Kim JM; Shin IS; Hwang MY; Yoon JS
    Psychiatry Res; 2006 Sep; 144(1):57-63. PubMed ID: 16904189
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cultural adaptation and validity of the Malay version of the brief psychiatric rating scale (BPRS-M) among patients with schizophrenia in a psychiatric clinic.
    Yee A; Ng BS; Hashim HMH; Danaee M; Loh HH
    BMC Psychiatry; 2017 Dec; 17(1):384. PubMed ID: 29197359
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Validation of Turkish version of brief negative symptom scale.
    Polat Nazlı I; Ergül C; Aydemir Ö; Chandhoke S; Üçok A; Gönül AS
    Int J Psychiatry Clin Pract; 2016 Nov; 20(4):265-71. PubMed ID: 27409157
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Assessing the sources of unreliability (rater, subject, time-point) in a failed clinical trial using items of the Positive and Negative Syndrome Scale (PANSS).
    Khan A; Yavorsky WC; Liechti S; DiClemente G; Rothman B; Opler M; DeFries A; Jovic S
    J Clin Psychopharmacol; 2013 Feb; 33(1):109-17. PubMed ID: 23277234
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score.
    Pilla Reddy V; Kozielska M; Suleiman AA; Johnson M; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
    Schizophr Res; 2013 May; 146(1-3):153-61. PubMed ID: 23473811
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Measuring pathology using the PANSS across diagnoses: Inconsistency of the positive symptom domain across schizophrenia, schizoaffective, and bipolar disorder.
    Anderson AE; Mansolf M; Reise SP; Savitz A; Salvadore G; Li Q; Bilder RM
    Psychiatry Res; 2017 Dec; 258():207-216. PubMed ID: 28899614
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Validity of the Spanish version of the Personal and Social Performance scale in schizophrenia.
    Apiquian R; Elena Ulloa R; Herrera-Estrella M; Moreno-Gómez A; Erosa S; Contreras V; Nicolini H
    Schizophr Res; 2009 Jul; 112(1-3):181-6. PubMed ID: 19398302
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Revisiting the 5 dimensions of the Positive and Negative Syndrome Scale.
    Levine SZ; Rabinowitz J
    J Clin Psychopharmacol; 2007 Oct; 27(5):431-6. PubMed ID: 17873671
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An excitement subscale of the Positive and Negative Syndrome Scale.
    Lindenmayer JP; Brown E; Baker RW; Schuh LM; Shao L; Tohen M; Ahmed S; Stauffer VL
    Schizophr Res; 2004 Jun; 68(2-3):331-7. PubMed ID: 15099614
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reliability and validity of the Medication Adherence Rating Scale in a cohort of patients with schizophrenia from Nigeria.
    Owie GO; Olotu SO; James BO
    Trends Psychiatry Psychother; 2018; 40(2):85-92. PubMed ID: 29768528
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dimensional approaches to schizophrenia: A comparison of the Bern Psychopathology scale and the five-factor model of the Positive and Negative Syndrome Scale.
    Lang FU; Müller-Stierlin AS; Walther S; Stegmayer K; Becker T; Jäger M
    Psychiatry Res; 2016 May; 239():284-90. PubMed ID: 27043275
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Positive and Negative Syndrome Scale--Spanish adaptation.
    Kay SR; Fiszbein A; Vital-Herne M; Fuentes LS
    J Nerv Ment Dis; 1990 Aug; 178(8):510-7. PubMed ID: 2380697
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Validity and reliability of the Spanish version of the Personal and Social Performance scale in adolescents with schizophrenia.
    Ulloa RE; Apiquian R; Victoria G; Arce S; González N; Palacios L
    Schizophr Res; 2015 May; 164(1-3):176-80. PubMed ID: 25728908
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Clinical assessment of schizophrenic syndromes (CASS): rationale, construction, reliability and sensitivity evaluation, and an attempt at normalization of the new diagnostic tool].
    Wciórka J; Anczewska M; Bembenek A; Gołebiewska M; Hochlewicz A; Nurowska K; Schaeffer E; Skowrońska J; Stanikowska I; Tarczyńska K
    Psychiatr Pol; 2000; 34(2):179-201. PubMed ID: 10974935
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relapse Risk Assessment for Schizophrenia Patients (RASP): A New Self-Report Screening Tool.
    Velligan D; Carpenter W; Waters HC; Gerlanc NM; Legacy SN; Ruetsch C
    Clin Schizophr Relat Psychoses; 2018 Jan; 11(4):224-235. PubMed ID: 29164930
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Defining and measuring negative symptoms of schizophrenia in clinical trials.
    Marder SR; Kirkpatrick B
    Eur Neuropsychopharmacol; 2014 May; 24(5):737-43. PubMed ID: 24275698
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A forced five-dimensional factor analysis and concurrent validity of the Positive and Negative Syndrome Scale in Mexican schizophrenic patients.
    Fresán A; De la Fuente-Sandoval C; Loyzaga C; García-Anaya M; Meyenberg N; Nicolini H; Apiquian R
    Schizophr Res; 2005 Jan; 72(2-3):123-9. PubMed ID: 15560957
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Psychometric validation of the consensus five-factor model of the Positive and Negative Syndrome Scale.
    Fong TC; Ho RT; Wan AH; Siu PJ; Au-Yeung FS
    Compr Psychiatry; 2015 Oct; 62():204-8. PubMed ID: 26343485
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: post hoc analysis of randomized clinical trial data.
    Robb AS; Carson WH; Nyilas M; Ali M; Forbes RA; Iwamoto T; Assunção-Talbott S; Whitehead R; Pikalov A
    J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):33-8. PubMed ID: 20166794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.